- Ọgwụgwọ
- Akaebe
- Neuroblastoma
- Tumor siri ike
- Akaebe
- TILS
- NK Cell Therapy
- Myasthenia Gravis (MG)
- Nnukwu ọrịa leukemia Lymphoblastic (B-ALL)
- Lupus Erythematosus System (SLE)
- Nnukwu ọrịa leukemia Lymphoblastic (T-ALL)
- Na-abụghị Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Na-ekesa nnukwu Lymphom B-cell
- B-lymphocytic leukemia
- Myeloma
CAR-T maka Hepatocellular Carcinoma
-
Cell CAR-T
CAR-T (Chimeric Antigen Nnabata T-cell) ọgwụgwọ bụ immunotherapy na-apụta nke na-agbanwe mkpụrụ ndụ T nke gị ka ịmata ma mebie mkpụrụ ndụ kansa nke ọma. Maka HCC, ọgwụgwọ a na-elekwasị anya na protein dị iche iche na mkpụrụ ndụ tumo, nwere ike inyekwu ihe uzo ozo ma ọ bụ imeju na ọgwụgwọ ọkọlọtọ.
Ọ na-agụnye ịnakọta na injinia mkpụrụ ndụ na-alụso ọrịa ọgụ n'ime ụlọ nyocha tupu iweghachi ha, na-achọ imezu ya nzaghachi na-adịgide adịgide ya na mmetụta sistemu dị ole na ole.
Ezubere na CAR-T Therapy maka Hepatocellular Carcinoma
Glypican-3 (GPC3) bụ isi ebumnuche maka ọgwụgwọ CAR-T na HCC n'ihi ngosipụta ya dị elu na mkpụrụ ndụ kansa imeju yana ọnụnọ pere mpe na anụ ahụ ndị okenye nwere ahụike.
GPC3 bụ protein n'elu cell nke na-akwalite uto tumor site na ịkwalite ụzọ mgbaàmà dị ka Wnt, nke na-ebute mmụba cancer. Site n'ịduzi mkpụrụ ndụ CAR-T ka ha kekọta GPC3, ọgwụgwọ ahụ na-elekwasị anya ọgụ mgbochi na mkpụrụ ndụ ọjọọ, na-echekwa ọrụ imeju nkịtị ka o kwere mee. Atụmatụ a ezubere iche dị mkpa maka ndị ọrịa nwere HCC dị elu bụ ndị na-anabataghị usoro ọgwụgwọ mbụ.
Kedu ka ọgwụgwọ CAR-T si arụ ọrụ: Usoro nke ime ihe
Emebere usoro ọgwụgwọ CAR-T iji jikwaa yana kwalite ihe nchekwa anụ ahụ gị:
- Nchịkọta: A na-enweta ihe atụ nke mkpụrụ ndụ T gị site n'usoro dị mfe yiri ịse ọbara.
- Injinia: N'ime ụlọ nyocha, mkpụrụ ndụ T ndị a na-agbanwe site na mkpụrụ ndụ ihe nketa iji gosipụta chimeric antigen receptor (CAR) nke na-amata kpọmkwem GPC3 na sel HCC.
- Nkwalite na Mgbasawanye: A na-eto mkpụrụ ndụ ndị a gbanwere n'ọtụtụ buru ibu ma rụọ ọrụ ka ha bụrụ ndị na-alụ ọgụ cancer.
- Infusion: A na-agbanyeghachi mkpụrụ ndụ CAR-T n'ime ọbara gị, ebe ha na-achọ ma jikọta na mkpụrụ ndụ tumor GPC3.
- Mwakpo: Mgbe ejikọtara ya, mkpụrụ ndụ CAR-T na-ewepụta akara iji mebie mkpụrụ ndụ kansa, nke nwere ike ibute mbelata etuto yana nleba anya na-alụso ọrịa ọgụ na-aga n'ihu.
Usoro a na-achọ ịnye nzaghachi na-adịgide adịgide, ọ bụ ezie na nleba anya dị mkpa iji jikwaa mmetụta ọ bụla metụtara mgbochi.
Ọgwụ GPC3 ezubere iche maka CAR-T maka carcinoma hepatocellular na-egosi arụmọrụ siri ike na ule ụlọ ọgwụ. N'ime ọmụmụ anyị nke ndị ọrịa 30 nwere GPC3-positive HCC bụ ndị dara tupu usoro ọgwụgwọ, ndị Nzaghachi ebumnobi bụ 56.6%, gụnyere 53.3% nzaghachi ele mmadụ anya n'ihu. Ọnụ ọgụgụ nchịkwa ọrịa ruru 86.7%, ya na etiti Ịlanarị ọnwa 13 na-enweghị ọganihu na mkpokọta nlanarị nke ọnwa 14.6. Usoro ọgwụgwọ ahụ adịghị mma, yana ọrịa ntọhapụ cytokine dị nro na mmetụta ndị nwere ike ịchịkwa. Anyị na-aga n'ihu na-asụ ụzọ ọgwụgwọ ndị a iji kwalite nsonaazụ maka ndị ọrịa cancer imeju.
Stereotactic ahu Radiotherapy (SBRT
Usoro radieshon a ziri ezi na-elekwasị anya n'obere etuto imeju nwere oke doses n'ime oge ole na ole, na-ebelata nha etuto ahụ ma nwee ike ịkwalite ntinye cell CAR-T ma na-ebelata mmebi nke anụ ahụ gbara ya gburugburu.
Ntinye aka
Usoro mmegide pere mpe dị ka ikuku redio ma ọ bụ ablation microwave na-emebi anụ ahụ site na okpomoku, na-eke gburugburu ebe mkpụrụ ndụ CAR-T nwere ike gbado anya nke ọma mkpụrụ ndụ kansa.
Chemoembolization transarterial (TACE)
Site na ibuga chemotherapy ozugbo na etuto ahụ site na akwara imeju na igbochi ọkọnọ ya, TACE na-ebelata etuto ahụ ma nwee ike imekọrịta ya na CAR-T site n'imebi ihe nchebe ọrịa cancer na imezi nzaghachi mgbochi.
Ịwa ahụ
Maka ndị ọrịa tozuru oke, imeju imeju akụkụ akụkụ nwere ike wepu ọrịa buru ibu, na-ekwe ka CAR-T lekwasị anya na ihe fọdụrụ na microscopic.
Ngwakọta ndị a na-achọ ịkwalite nsonaazụ mgbe ị na-ebute ụzọ nkasi obi na ahụike imeju gị.
Ajụjụ a na-ajụkarị
- Usoro ọgwụgwọ CAR-T ọ dabara maka ndị ọrịa HCC niile? A na-ele ya anya maka ndị nwere etuto dị mma GPC3 bụ ndị nwere ọganihu na usoro ọgwụgwọ ọkọlọtọ. Nyocha nke ọma, gụnyere nnwale biomarker, na-ekpebi ntozu.
- Kedu mmetụta m nwere ike ịnweta? Ndị a na-ahụkarị na-agụnye mgbaàmà ndị yiri flu sitere na CRS, ike ọgwụgwụ, ma ọ bụ mgbanwe ọrụ imeju nwa oge, nke a na-enyocha ma na-agwọ ya ozugbo.
- Ogologo oge ole ka usoro ọgwụgwọ ahụ dị? Site na nchịkọta cell ruo na infusion, ọ na-ewekarị izu ole na ole, na-esochi ya mgbe niile iji chọpụta nzaghachi.
Ọ bụrụ na ị na-eme nchọpụta Usoro ọgwụgwọ CAR-T maka hepatocellular carcinoma, Ndị otu anyị na Bioocus dị njikere ikwurịta ka ọ ga-esi tinye n'ime atụmatụ nlekọta gị. Gakwuru maka ndụmọdụ iji ntuziaka dabere n'ihe akaebe nyochaa nhọrọ gị - njem gị maka njikwa ka mma na-amalite site na nhọrọ ndị ama ama.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.